$OPK ~ Opko's next-generation prostate cancer te

$OPK ~ Opko's next-generation prostate cancer test should reduce unnecessary biopsies by 50%

Opko just launched its new prostate cancer diagnostic test (called the 4KScore) in Europe and should begin selling in the United States later this year. This test is being launched in the U.S. as a Laboratory Developed Test ("LDT") under FDA guidelines, and no additional FDA approvals are necessary. Once investors realize that [b]Opko will be generating a new revenue stream in a multibillion-dollar market[/b], we could see major share price appreciation.

This is as per an article on Seeking Alpha! http://seekingalpha.com/article/902221-opko-s...urce=yahoo